A Multi-Center,Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Trial Profile

A Multi-Center,Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SHIP
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2016 Status changed from recruiting to discontinued due to enrollment challenges as reported by ClinicalTrials.gov.
    • 22 Feb 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top